Attached files

file filename
EX-99.1 - EX-99.1 - ACURA PHARMACEUTICALS, INCv238490_ex99-1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
 


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934

October 31, 2011
Date of Report (Date of earliest event reported)
 

ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)


 
State of New York
1-10113
11-0853640
(State of Other Jurisdiction
(Commission File Number)
(I.R.S. Employer
of Incorporation)
 
Identification Number)

616 N. North Court, Suite 120
 Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

¨           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

¨           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
    
 
 

 
    
Item 2.02
Results of Operations and Financial Condition

On October 31, 2011 we issued a press release disclosing the financial results for our third quarter ended September 30, 2011.  A copy of our press release is being furnished as Exhibit 99.1 hereto.

Item 9.01 
Financial Statements and Exhibits

 
Exhibit Number
 
Description
     
99.1
 
Press Release dated October 31, 2011 announcing financial results for the third quarter ended September 30, 2011
 
 

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.
   
By:
/s/ Peter A. Clemens
 
Peter A. Clemens
 
Senior Vice President & Chief Financial Officer

Date:           October 31, 2011
 
 

 
Exhibit Index
  
Exhibit Number
 
Description
     
99.1
 
Press Release dated October 31, 2011 announcing financial results for the third quarter ended September 30, 2011